Fortrea Holdings Inc. reports news on its role as a global contract research organization serving the life sciences industry. The company provides phase I-IV clinical trial management, clinical pharmacology and consulting services for biopharmaceutical, biotechnology, medical device and diagnostic customers.
Recurring Fortrea updates include quarterly and annual financial results, book-to-bill trends, guidance, debt and capital actions, executive and board matters, equity award disclosures and technology used in clinical trial operations. Company announcements also cover platforms such as Fortrea Intelligent Technology and Xcellerate, which support trial workflow, oversight and site-facing processes.
Fortrea (FTRE) reported third-quarter 2026 net income of $0.6 million, returning to profitability despite lower revenue than a year earlier. Revenue was $691.5 million versus $701.3 million, while diluted earnings per share were $0.01 versus a $0.17 loss. Adjusted EBITDA—earnings before interest, taxes, depreciation and amortization, with additional adjustments—rose to $58.0 million from $50.7 million.
Quarterly operating cash flow was $60.8 million and free cash flow was $52.5 million. A contract review reduced backlog by $558 million to $7,316 million, without affecting historical results, 2026 guidance or near-term revenue estimates. Orders relative to revenue, or book-to-bill, were 1.12x for both the quarter and trailing 12 months. Fortrea raised its full-year guidance midpoints and narrowed the ranges, expecting revenue of $2,665 million–$2,690 million and adjusted EBITDA of $210 million–$218 million.
Fortrea (FTRE) will participate in the Jefferies Global Healthcare Conference in London on November 17, 2026, with a fireside chat and investor meetings.
CEO Anshul Thakral, CFO Jason Knoblauch and SVP of Investor Relations Tracy Krumme will attend. The fireside chat runs from 8:30–8:55 AM EST, or 1:30–1:55 PM GMT. A live webcast and video replay will be available through the Events section of Fortrea’s investor relations website.
Fortrea (FTRE) and Omico announced a collaboration to connect cancer patients in Australia with clinical trials matched to their biomarkers. The effort combines Fortrea’s oncology trial experience with Omico’s Precision Oncology Screening Platform Enabling Clinical Trials (PrOSPeCT), which uses molecular profiling to help match patients with studies and targeted therapies.
Omico will support Fortrea’s clients with patient population insights, genomic profiling, trial matching, real-world oncology data and Australian referral pathways. Fortrea says the collaboration aims to improve study planning, site selection and recruitment while expanding access to biomarker-driven research. Omico’s clinic-genomic databases include more than 23,000 consented patients, and it has received referrals from more than 1,600 clinicians across Australia.
Fortrea (FTRE) completed its acquisition of Worldwide Clinical Trials’ Early Phase Services division for approximately $45 million in cash.
The acquisition adds a 200-bed clinical research unit in San Antonio, a 60,000-square-foot bioanalytical laboratory in Austin and a biospecimen storage facility in Pflugerville, Texas. It expands Fortrea’s early-phase capacity to more than 570 beds globally and adds in-house capabilities to analyze large and small molecules in biological samples. The acquired operations are now part of Fortrea’s Clinical Pharmacology Services business unit.
Fortrea expects the combined platform to reduce handoffs between clinical and laboratory functions, improve turnaround times and accommodate larger, more complex studies. The companies also entered into agreements intended to maintain continuity for clients, employees and ongoing programs during the transition.
Fortrea (FTRE) will release its third quarter 2026 financial results before the market opens on October 29, 2026. The company will host a conference call at 8:00 a.m. ET that day to discuss the results. A live webcast will be available at investors.fortrea.com, with a replay posted in the site's Events and Presentations section after the call.
Fortrea (FTRE) granted inducement equity awards under Nasdaq Listing Rule 5635(c)(4) on September 10, 2026, to five newly hired employees, including its new Chief Financial Officer, Jason Knoblauch.
The awards to Mr. Knoblauch comprise 106,755 performance share units (PSUs), which may vest at the end of a three-year period subject to specified performance goals, and 144,434 restricted stock units (RSUs) that vest in three equal annual installments from the grant date. Vesting of these awards generally requires his continuous employment, with the possibility of earlier vesting upon a change of control and certain termination events. All awards were approved by the independent directors and granted under Fortrea’s Amended and Restated 2025 Inducement Award Plan.
Fortrea (FTRE) will participate in three investor conferences in September 2026, featuring CEO Anshul Thakral, CFO Jason Knoblauch and SVP of Investor Relations Tracy Krumme.
Management will join a fireside chat and hold 1x1 and group meetings at the Baird 2026 Global Healthcare Conference in New York on September 15, 2026, from 2:00–2:30 p.m. EDT, with a live webcast and replay available via Fortrea’s Investor Relations “Events” page. They will also conduct 1x1 and group meetings at the Deutsche Bank 2026 Healthcare Summit in New York on September 16, 2026, and at the virtual RBC Pharma Services and Life Science Tools Conference on September 22, 2026. Investors seeking meetings are directed to contact their banking representatives.
Fortrea (FTRE) agreed on September 2, 2026 to acquire Worldwide Clinical Trials’ Early Phase Services division in an all-cash deal valued at approximately $45 million.
The transaction covers a 60,000 sq. ft. GLP bioanalytical lab in Austin, a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, and a biospecimen storage facility in Pflugerville, Texas. These assets add in-house large and small molecule bioanalytical capabilities and expand Fortrea’s North American clinical research unit footprint, enabling more integrated, faster early-phase studies from first-in-human through proof-of-concept.
Early Phase Services will be integrated into Fortrea’s Clinical Pharmacology Services unit after closing, which is subject to regulatory and license approvals and final services agreements. Worldwide plans to focus investment on its rapidly growing late-stage business in oncology, neuroscience, internal medicine and rare disease, while both companies intend to maintain continuity for employees, customers and ongoing programs through strategic alliance and services agreements.
Fortrea (Nasdaq: FTRE) reported second quarter 2026 revenue of $678.2 million, down from $710.3 million in 2025, with a book-to-bill ratio of 1.06x and backlog of $7.8 billion. GAAP net loss was $(13.2) million, or $(0.14) per diluted share, versus a prior-year loss of $(374.9) million that included a large goodwill impairment.
Adjusted net income was $22.7 million (EPS $0.23) and adjusted EBITDA was $58.7 million, both above 2025 levels. First-half 2026 adjusted EBITDA reached $105.7 million. Cash from operations in Q2 was $28.9 million and free cash flow $19.9 million. Fortrea increased full-year 2026 guidance to revenue of $2,620–$2,690 million and adjusted EBITDA of $205–$220 million, reflecting management’s higher outlook for the year.
Fortrea (Nasdaq: FTRE) will release its second quarter 2026 financial results before the market opens on Wednesday, July 29, 2026. The company will host a conference call at 8:00 a.m. ET that same day to discuss the results, with access via pre-registration for dial-in details and a unique PIN, and a live webcast and replay available at investors.fortrea.com.